Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Apr 23:15:1394878.
doi: 10.3389/fphar.2024.1394878. eCollection 2024.

Direct antitumor activity of bevacizumab: an overlooked mechanism?

Zhiyong Wang  1 , Jiaqi Li  1 , Jinjin Guo  1 , Pei Wei  1
Affiliations

Direct antitumor activity of bevacizumab: an overlooked mechanism?

Zhiyong Wang et al. Front Pharmacol. .
No abstract available

Keywords: antiangiogenesis; bevacizumab; direct antitumor activity; tumor cells; vascular endothelial growth factor A.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
VEGFA signaling in endothelial and tumor cells. VEGFA, secreted by tumor and stromal cells, such as endothelial cells, immune cells, and fibroblasts, binds to VEGFR and co-receptors on the surface of endothelial or tumor cells, activating intracellular VEGFA signaling pathways. In endothelial cells, activated VEGFA signaling promotes cell survival, proliferation, and migration, leading to the induction of tumor angiogenesis. In tumor cells, the activation of the VEGFA pathway enhances cell survival, proliferation, and resistance to apoptosis, facilitating tumor cell growth. VEGFA targets both endothelial and tumor cells; correspondingly, bevacizumab exerts anti-angiogenic and direct antitumor effects by neutralizing VEGFA.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Adan A., Kiraz Y., Baran Y. (2016). Cell proliferation and cytotoxicity assays. Curr. Pharm. Biotechnol. 17 (14), 1213–1221. 10.2174/1389201017666160808160513 - DOI - PubMed
    1. Alonso-Diez Á., Cáceres S., Peña L., Crespo B., Illera J. C. (2021). Anti-angiogenic treatments interact with steroid secretion in inflammatory breast cancer triple negative cell lines. Cancers 13 (15), 3668. 10.3390/cancers13153668 - DOI - PMC - PubMed
    1. Apte R. S., Chen D. S., Ferrara N. (2019). VEGF in signaling and disease: beyond discovery and development. Cell 176 (6), 1248–1264. 10.1016/j.cell.2019.01.021 - DOI - PMC - PubMed
    1. Becker S., Bohn P., Bouyeure-Petit A. C., Modzelewski R., Gensanne D., Picquenot J. M., et al. (2015). Bevacizumab enhances efficiency of radiotherapy in a lung adenocarcinoma rodent model: role of αvβ3 imaging in determining optimal window. Nucl. Med. Biol. 42 (12), 923–930. 10.1016/j.nucmedbio.2015.08.002 - DOI - PubMed
    1. Bergers G., Benjamin L. E. (2003). Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer. 3 (6), 401–410. 10.1038/nrc1093 - DOI - PubMed

Grants and funding

The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This work was supported by the grants from the National Natural Science Foundation of China (No. 81503104), the Guizhou Province Science and Technology Foundation [(2021)564], and the Scientific Research Foundation of Zunyi Medical University (Nos F955 and FZH004).

LinkOut - more resources